Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) EVP Thomas Bartrum sold 1,506 shares of the firm's stock in a transaction on Friday, May 10th. The stock was sold at an average price of $17.88, for a total value of $26,927.28. Following the completion of the sale, the executive vice president now owns 102,356 shares of the company's stock, valued at $1,830,125.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Thomas Bartrum also recently made the following trade(s):
- On Tuesday, April 30th, Thomas Bartrum sold 2,252 shares of Privia Health Group stock. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84.
Privia Health Group Stock Performance
Privia Health Group stock traded up $0.02 during mid-day trading on Monday, reaching $17.99. 825,799 shares of the company were exchanged, compared to its average volume of 951,398. Privia Health Group, Inc. has a 12-month low of $16.90 and a 12-month high of $29.42. The business has a fifty day moving average of $19.32 and a 200 day moving average of $20.95. The firm has a market cap of $2.15 billion, a P/E ratio of 119.93, a PEG ratio of 2.24 and a beta of 0.81.
Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. The business had revenue of $440.80 million for the quarter, compared to analysts' expectations of $425.81 million. During the same quarter in the previous year, the firm posted $0.14 EPS. Privia Health Group's revenue was up 21.0% on a year-over-year basis. Sell-side analysts predict that Privia Health Group, Inc. will post 0.26 EPS for the current year.
Analyst Ratings Changes
Several brokerages have issued reports on PRVA. Evercore ISI dropped their target price on Privia Health Group from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Wednesday, February 28th. TD Cowen cut their price objective on Privia Health Group from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, March 1st. Stifel Nicolaus decreased their target price on Privia Health Group from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, May 1st. Citigroup started coverage on shares of Privia Health Group in a report on Monday, April 22nd. They issued a "buy" rating and a $25.00 price target on the stock. Finally, Barclays assumed coverage on shares of Privia Health Group in a research report on Wednesday, March 6th. They issued an "equal weight" rating and a $22.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Privia Health Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.
Read Our Latest Stock Analysis on Privia Health Group
Hedge Funds Weigh In On Privia Health Group
A number of institutional investors have recently bought and sold shares of PRVA. Park Place Capital Corp boosted its holdings in shares of Privia Health Group by 115.4% in the 1st quarter. Park Place Capital Corp now owns 2,492 shares of the company's stock valued at $49,000 after acquiring an additional 1,335 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in Privia Health Group by 44.9% in the fourth quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company's stock valued at $75,000 after purchasing an additional 1,003 shares during the last quarter. Covestor Ltd grew its position in Privia Health Group by 25.5% during the 1st quarter. Covestor Ltd now owns 5,292 shares of the company's stock worth $104,000 after purchasing an additional 1,076 shares during the period. SG Americas Securities LLC purchased a new position in shares of Privia Health Group during the 1st quarter valued at about $131,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of Privia Health Group during the 4th quarter valued at about $158,000. 94.48% of the stock is owned by hedge funds and other institutional investors.
About Privia Health Group
(
Get Free Report)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Privia Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.
While Privia Health Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
